Imugene Limited has received a significant boost with the United States Food and Drug Administration (FDA) granting Orphan Drug Designation (ODD) to its experimental therapy, CF33-hNIS (VAXINIA), aimed at treating bile tract cancer. This designation propels Imugene’s clinical-stage oncolytic virotherapy forward, positioning the Sydney-based company as a key player in the development of innovative cancer […]
Incyte has announced new early-stage clinical data for INCB123667, a highly selective and potential first-in-class CDK2 inhibitor, showing promising results in patients with advanced solid tumors, particularly ovarian cancer. The data were presented during the European Society of Medical Oncology (ESMO) Congress 2024 and later updated during an Incyte investor event, emphasising the potential of […]
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that Health Canada has granted approval for KEYTRUDA (pembrolizumab) in combination with enfortumab vedotin for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) who have not received prior systemic therapy for this condition. This decision […]
Exscientia plc (Nasdaq: EXAI), a pioneer in AI-driven drug discovery, has reached a strategic milestone by acquiring full ownership of the oral CDK7 inhibitor program from GT Apeiron, taking control of the promising compound GTAEXS617 (‘617) along with all associated intellectual property. Under the terms of the agreement, Exscientia will pay GT Apeiron $10 million […]
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company, has announced encouraging results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial. The study evaluates the effectiveness of eftilagimod alfa (efti) combined with Merck & Co., Inc.’s KEYTRUDA (pembrolizumab) in treating patients with recurrent or metastatic head and neck squamous cell carcinoma (1L […]
Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase 3 CARTITUDE-4 study, which is pivotal in the evolving landscape of multiple myeloma treatment. This significant study assesses the effectiveness of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) against the standard therapies, which include combinations of pomalidomide, bortezomib, and dexamethasone […]
Antengene Corporation Limited, a commercial-stage global biopharmaceutical company, has announced a significant milestone with the China National Medical Products Administration (NMPA) approving a new indication for XPOVIO (selinexor). This approval allows the use of XPOVIO as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), one of the most […]
Ascentage Pharma, a leading global biopharmaceutical company specializing in novel therapies for cancer and other serious diseases, has announced the receipt of a US$100 million option payment from Takeda. This payment is part of an Exclusive Option Agreement that grants Takeda the opportunity to license the potentially groundbreaking BCR-ABL inhibitor, olverembatinib. – Substantial Financial Commitment: […]
Signet Therapeutics, a pioneering biotech company, has achieved a significant milestone with the US Food and Drug Administration (FDA)’s Investigational New Drug (IND) approval of its drug candidate, sigx1094, for the treatment of diffuse gastric cancer (DGC). This marks the introduction of the first targeted therapy for DGC, a disease currently lacking effective treatment options. […]
Marine organisms offer a vast reservoir of cytotoxic compounds with potential therapeutic applications in treating various cancers. These biomedicines, known as marine drugs, are derived from a variety of marine species and have shown promise in pharmacological studies due to their unique chemical properties and modes of action. Marine Drugs and Their Sources Several marine […]
